ArticleBMC cancer2018

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.

Sheng-Long Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.